Nutraceuticals
Back

Products

100 years of botanical excellence mean a wide range of botanical derivatives. Search for them.

Go to section
Back

Things to watch

Go to section
Back

Media and news

Here is the right place where you can read all the latest news and information about Indena’s world.

See through science

See through science

Casperome®

Casperome®

Scroll to see more

Peer-reviewed science on Casperome®

Good news for gut health

A randomized, double-blind, placebo-controlled trial on 49 adults with acute diarrhea administered with 250 mg of Casperome® 2 times per day, showed a significant reduction frequency of stools and duration of diarrhea, along with associated secondary conditions (Figure 1). At the end of the study, the percentage of subjects free from diarrhea within 5 days of supplementation was 95.8% in the treated group vs 76% in the placebo (Figure 2). No side effects have been observed. Mechanistic evaluations also proved that the Boswellia serrata extract can act as a Ca2+ channels modulator on intestinal smooth muscles.1

casperome_new 03

Figure 1: Graphic representation of the mean number of stools over time.1

casperome_new 04

Figure 2: The log-rank test showed a median time of a 3 days of becoming healthy for the supplemented group and a median of 5 days for the placebo group.1

A study involved 43 participants with a story of Ulcerative Colitis that received an oral daily Casperome® supplementation (n = 22) or no supplementation (n = 21) for 4 weeks. The Casperome® group experienced overall better well-being feeling compared to the control, that required some treatment and medical consultations.

casperome_new 05-ok

Figure 3: Evaluation criteria, observed before and at the end of the study.2

Another trial involved 71 healthy subjects with idiopathic gastrointestinal discomforts. The participants were divided into 3 groups and randomized with Hyoscine butylbromide (Buscopan®), Papaverine hydrochloride 10 mg + belladonna (A. belladonna) and Casperome®. The number of subjects experiencing persistent gastrointestinal well-being counted more after the observational period in Casperome® supplemented group (from 42% to 87.5%). Consistently, the number of subjects who needed medical attention significantly decreased to 4.1%.3

Finally, in a 6-month study on 69 participants, subjects on Casperome® showed lower mean score values, compared with the standard management group, for almost all output. The incidence of minimal adverse events was significantly higher in the standard management group.4

Buscopan® is a registered trademark of Sanofi SA.

The ally for musculoskeletal stress

Casperome® has beneficial effects in case of muscoskeletal and sport stress in general. All studies are consistent in showing a prompt decrease of discomforts and amelioration of functionality of the affected area after Casperome® administration, without relevant adverse events.

In a human study on young rugby players with acute knee stress, after a 4-week follow-up, only 6 subjects of those administrated with Casperome® show local stress vs. 25 at baseline. Moreover, the administrated group has significantly less need of other support compared to the standard-management group.5

Great bioabsorption

PK OF CASPEROME® VS BASIC B. SERRATA EXTRACT DELIVERED BOSWELLIC ACIDS.
Casperome® delivers boswellic acids in average 3 times more efficiently and their peak concentration of boswellic acids are reached faster than in the baseline conditions than the basic extract (Figures 4 and 5).6

casperome-02

Figure 4: Total boswellic acids mean plasma concentrations (ng/mL) profile after administration of Casperome®(CSP) and not (BE).6

casperome-01

Figure 5: Proportion of subjects needing analgesic support (%), after a 4-week follow-up, either with Casperome®standard management or only standard management.6

BIBLIOGRAPHY
1. Giacosa, A et al. Nutrients 2022, 14, 1858.
2. Pellegrini L. et al.Eur Rev Med Pharmacol Sci 2016, 20: 2695-2700.
3. Riva, A., et al. Phytomedicine 23.12, 1375-1382 (2016).
4. Belcaro, G., et al. European Review for Medical and Pharmacological Sciences 21 (2017): 2249-2254.
5. Riva A, et al Minerva Gastroenterol Dietol. 2019 Mar;65(1):30-35.
6. Riva, A., et al.Eur Rev Med Pharmacol Sci 21.22, 5258-5263 (2017).

Indena - Science is our nature

Sorry, our website doesn't support IE11 and older versions

For a better experience try a modern browser:

Indena

Indena

This is a private file, to request the download of this resource, please fullfill the fields below.